ALFA Finder| Revenue growth | H1 standalone CC +17%; Q2 total income +32% |
|---|---|
| Margins | Net material cost 32% of sales vs 40% last year |
| Demand visibility | CS RFPs rising; 60-70 projects at any time; no capacity shortage foreseen |
| Management confidence | Confident on CS pipeline; declined to quantify validation revenue |
Growth
Q2 PBT ₹1,505 cr (+65%). H1 total income ₹6,907 cr vs ₹5,389 cr. H1 standalone constant-currency revenue +17%.
Outlook
Guides double-digit revenue growth; capex ~₹2,000 cr ±20% yearly for 2–3 years; three dedicated projects commercialise over coming quarters.
Risks
Middle East disruption raising solvent and freight costs; generics pricing pressure; ₹1,197 cr inventory build; weak operating cash flow.
Investor Presentation filed with BSE, NSE: DIVISLAB. Summary written with AI assistance from the document.
Divi's Laboratories Ltd: key numbers
- Share price
- ₹11,442.00
- Market cap
- ₹3,03,749 Cr
- Revenue (annual)
- ₹10,560 Cr
- Net profit (annual)
- ₹2,568 Cr
- P/E (TTM)
- 90.3×Sector 43.7×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 20.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Divi's Laboratories Ltd
All →Divi's Laboratories Q2 FY27 Results: Net Profit ₹1,127 Cr, Up 63.6% YoY
Divi's Laboratories Ltd reported revenue from operations of ₹3,676 Cr (+35.4% YoY) and net profit of ₹1,127 Cr (+63.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,127 Cr · +63.6% YoY
Divi's Laboratories Board Meeting Date
Divi's Laboratories will hold a board meeting on November 07, 2026, to approve unaudited standalone and consolidated financial results for the quarter ended September 30, 2026.
Divi's Laboratories Other Announcement
Divis Laboratories Ltd has submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI Regulation 31.
Divi's Laboratories Other Announcement
Immediate relatives of the company purchased 462 shares for a total consideration of Rs. 0.43 Crore in the open market.
- Value
- ₹0.43 Cr
Divi's Laboratories Other Announcement
Divis Laboratories Ltd reported a share pledge by Designated Person Nimmagadda Venkata Anirudh involving securities valued at ₹3.33 Crore. Additionally, Joshita Divi acquired shares worth ₹0.96 Crore via market purchase.
- Value
- ₹4.29 Cr
Divi's Laboratories Other Announcement
An immediate relative of a Divis Laboratories promoter bought equity shares worth ₹0.58 Crore through a market purchase.
- Value
- ₹0.58 Cr